JP2024522385A5 - - Google Patents

Info

Publication number
JP2024522385A5
JP2024522385A5 JP2023554016A JP2023554016A JP2024522385A5 JP 2024522385 A5 JP2024522385 A5 JP 2024522385A5 JP 2023554016 A JP2023554016 A JP 2023554016A JP 2023554016 A JP2023554016 A JP 2023554016A JP 2024522385 A5 JP2024522385 A5 JP 2024522385A5
Authority
JP
Japan
Prior art keywords
protein
positions
fusion
immunogenic composition
hmpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/059492 external-priority patent/WO2022214678A2/en
Publication of JP2024522385A publication Critical patent/JP2024522385A/ja
Publication of JP2024522385A5 publication Critical patent/JP2024522385A5/ja
Pending legal-status Critical Current

Links

JP2023554016A 2021-04-09 2022-04-08 ヒトメタニューモウイルスワクチン Pending JP2024522385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21167609.3 2021-04-09
EP21167609 2021-04-09
PCT/EP2022/059492 WO2022214678A2 (en) 2021-04-09 2022-04-08 Human metapneumo virus vaccine

Publications (2)

Publication Number Publication Date
JP2024522385A JP2024522385A (ja) 2024-06-19
JP2024522385A5 true JP2024522385A5 (enExample) 2025-04-15

Family

ID=75441775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554016A Pending JP2024522385A (ja) 2021-04-09 2022-04-08 ヒトメタニューモウイルスワクチン

Country Status (10)

Country Link
US (2) US20240181034A1 (enExample)
EP (2) EP4319804A2 (enExample)
JP (1) JP2024522385A (enExample)
KR (1) KR20230167017A (enExample)
CN (1) CN117279659A (enExample)
AU (1) AU2022255923A1 (enExample)
BR (1) BR112023017274A2 (enExample)
CA (1) CA3210412A1 (enExample)
MX (1) MX2023010370A (enExample)
WO (2) WO2022214678A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
WO2025119162A1 (zh) * 2023-12-04 2025-06-12 深圳深信生物科技有限公司 偏肺病毒(mpv)疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119971017B (zh) * 2025-04-16 2025-08-05 北京华诺泰生物医药科技有限公司 一种hmpv疫苗组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
EP4400115A3 (en) 2011-12-06 2024-10-23 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
KR20220010478A (ko) * 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
US20240067681A1 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
ES3058501T3 (en) Rsv f protein mutants
JPH11508769A (ja) C型肝炎に対するワクチン
IL200341A (en) Method for the preparation of immunogenic particles containing influenza a m2e protein fused to hepatitis b virus core protein
JP2024508683A5 (enExample)
CN117279659A (zh) 人偏肺病毒疫苗
ES2239758T3 (es) Glicoproteina de fusion de cmvh y vhs.
JPH07508520A (ja) 組合せポリペプチド抗原
JP2025509352A5 (enExample)
CN117396493A (zh) 氨基酸、核苷酸和表达它们的载体及其在预防沙贝病毒感染中的用途
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
AU2018342997C1 (en) Cutaneous papilloma virus vaccine
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤
HK40098178A (en) Human metapneumovirus vaccine
HK40051815A (en) Vaccine against rsv comprising modified f polypeptide
RU2023124900A (ru) Композиции, содержащие адъюванты sbi, и способы их применения
HK1250939B (en) Vaccine against rsv